BSE:500660

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

GlaxoSmithKline Pharmaceuticals

Executive Summary

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. More Details


Snowflake Analysis

Flawless balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has GlaxoSmithKline Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 500660 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 500660's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

1.8%

500660

2.1%

IN Pharmaceuticals

1.2%

IN Market


1 Year Return

-8.0%

500660

51.2%

IN Pharmaceuticals

10.4%

IN Market

Return vs Industry: 500660 underperformed the Indian Pharmaceuticals industry which returned 48.5% over the past year.

Return vs Market: 500660 underperformed the Indian Market which returned 8.3% over the past year.


Shareholder returns

500660IndustryMarket
7 Day1.8%2.1%1.2%
30 Day5.9%5.9%12.1%
90 Day-1.5%6.4%12.6%
1 Year-5.6%-8.0%53.0%51.2%12.4%10.4%
3 Year33.0%25.8%43.1%39.6%10.0%4.6%
5 Year3.2%-4.9%12.1%8.2%59.8%47.8%

Long-Term Price Volatility Vs. Market

How volatile is GlaxoSmithKline Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is GlaxoSmithKline Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

19.83x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: 500660 (₹1552.05) is trading above our estimate of fair value (₹486.55)

Significantly Below Fair Value: 500660 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 500660 is unprofitable, so we can't compare its PE Ratio to the IN Pharmaceuticals industry average.

PE vs Market: 500660 is unprofitable, so we can't compare its PE Ratio to the Indian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 500660's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 500660 is overvalued based on its PB Ratio (19.8x) compared to the IN Pharmaceuticals industry average (2.2x).


Next Steps

Future Growth

How is GlaxoSmithKline Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

32.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 500660 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (7.2%).

Earnings vs Market: 500660 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 500660's is expected to become profitable in the next 3 years.

Revenue vs Market: 500660's revenue (10.6% per year) is forecast to grow slower than the Indian market (11.5% per year).

High Growth Revenue: 500660's revenue (10.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 500660's Return on Equity is forecast to be high in 3 years time (31.4%)


Next Steps

Past Performance

How has GlaxoSmithKline Pharmaceuticals performed over the past 5 years?

-23.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 500660 is currently unprofitable.

Growing Profit Margin: 500660 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 500660 is unprofitable, and losses have increased over the past 5 years at a rate of 23.5% per year.

Accelerating Growth: Unable to compare 500660's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 500660 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (26%).


Return on Equity

High ROE: 500660 has a negative Return on Equity (-25.3%), as it is currently unprofitable.


Next Steps

Financial Health

How is GlaxoSmithKline Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 500660's short term assets (₹17.9B) exceed its short term liabilities (₹11.1B).

Long Term Liabilities: 500660's short term assets (₹17.9B) exceed its long term liabilities (₹3.0B).


Debt to Equity History and Analysis

Debt Level: 500660 is debt free.

Reducing Debt: 500660 has no debt compared to 5 years ago when its debt to equity ratio was 0.1%.

Debt Coverage: 500660 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 500660 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is GlaxoSmithKline Pharmaceuticals's current dividend yield, its reliability and sustainability?

1.29%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 500660's dividend (1.29%) is higher than the bottom 25% of dividend payers in the Indian market (0.52%).

High Dividend: 500660's dividend (1.29%) is low compared to the top 25% of dividend payers in the Indian market (2.1%).


Stability and Growth of Payments

Stable Dividend: 500660's dividend payments have been volatile in the past 10 years.

Growing Dividend: 500660's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: 500660 is paying a dividend but the company is unprofitable.


Future Payout to Shareholders

Future Dividend Coverage: 500660's dividends in 3 years are forecast to be covered by earnings (69.7% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Sridhar Venkatesh

0.58

Tenure

Mr. Sridhar Venkatesh serves as Managing Director at GlaxoSmithkline Pharmaceuticals Limited since April 1, 2020. Mr. Venkatesh served as the Commercial Head of Pharmaceuticals at GlaxoSmithkline Pharmaceu...


Leadership Team

NamePositionTenureCompensationOwnership
Puja Thakur
South Asia Finance Director2.83yrs₹43.38mno data
Raju Krishnaswamy
Executive Director of Technical9.25yrs₹28.94mno data
Ajay Nadkarni
VP of Administration & Real Estate and Company Secretaryno data₹13.24mno data
Meenakshi Priyam
Executive Vice President of Human Resources3yrs₹41.34mno data
Anil Iyer
Chief Commercial Officer of Pharmaceuticals3.17yrs₹45.42mno data
Sridhar Venkatesh
Managing Director0.58yrno datano data
S. Balasubramanian
Vice President of Ethics & Compliance2.08yrsno datano data
S. Zota
Executive Vice President of Legal0.67yrno datano data
Ransom D'Souza
Vice President of Communications & Government Affairs3.58yrsno datano data
Sumer Dheri
Executive Vice President of Vaccines3.58yrsno datano data
Sukanya Choudhury
Executive Vice-President of Regulatory Affairsno datano datano data
Deepshikha Jakate
Regional Quality Head South Asia & Vice President of Quality2.75yrsno datano data

2.9yrs

Average Tenure

Experienced Management: 500660's management team is considered experienced (2.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Puja Thakur
South Asia Finance Director2.83yrs₹43.38mno data
Raju Krishnaswamy
Executive Director of Technical9.25yrs₹28.94mno data
Sridhar Venkatesh
Managing Director0.58yrno datano data
Renu Karnad
Independent Chairperson1.58yrs₹2.90m0.00035%
₹ 922.1k
Nihal Vijaya Devadas Kaviratne
Non-Executive Independent Director15.33yrs₹2.25mno data
Damodarannair Sundaram
Non-Executive Independent Director11.33yrs₹2.10mno data
Subesh Williams
Non Executive Director3.58yrsno datano data
Pradeep Bhide
Non-Executive Independent Director10.08yrs₹2.20mno data
Anami Roy
Non-Executive Independent Director9yrs₹1.80mno data
Sunita Maheshwari
Additional Independent Director0.50yrno datano data

6.3yrs

Average Tenure

67.5yo

Average Age

Experienced Board: 500660's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

GlaxoSmithKline Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: GlaxoSmithKline Pharmaceuticals Limited
  • Ticker: 500660
  • Exchange: BSE
  • Founded: 1924
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹263.443b
  • Shares outstanding: 169.41m
  • Website: https://www.india-pharma.gsk.com

Number of Employees


Location

  • GlaxoSmithKline Pharmaceuticals Limited
  • GSK House
  • Dr. Annie Besant Road
  • Mumbai
  • Maharashtra
  • 400030
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
500660BSE (Mumbai Stock Exchange)YesEquity SharesININRJun 1996
GLAXONSEI (National Stock Exchange of India)YesEquity SharesININRJun 1996

Biography

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescript...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/01 12:18
End of Day Share Price2020/12/01 00:00
Earnings2020/09/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.